GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioSpecifics Technologies Corp (NAS:BSTC) » Definitions » PB Ratio

BioSpecifics Technologies (BioSpecifics Technologies) PB Ratio : 4.81 (As of Apr. 26, 2024)


View and export this data going back to 1991. Start your Free Trial

What is BioSpecifics Technologies PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), BioSpecifics Technologies's share price is $88.53. BioSpecifics Technologies's Book Value per Share for the quarter that ended in Sep. 2020 was $18.42. Hence, BioSpecifics Technologies's PB Ratio of today is 4.81.

The historical rank and industry rank for BioSpecifics Technologies's PB Ratio or its related term are showing as below:

BSTC' s PB Ratio Range Over the Past 10 Years
Min: 2.63   Med: 5.04   Max: 12.63
Current: 4.67

During the past 13 years, BioSpecifics Technologies's highest PB Ratio was 12.63. The lowest was 2.63. And the median was 5.04.

BSTC's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.37 vs BSTC: 4.67

During the past 12 months, BioSpecifics Technologies's average Book Value Per Share Growth Rate was 8.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 27.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 30.40% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 36.60% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of BioSpecifics Technologies was 47.20% per year. The lowest was -45.30% per year. And the median was 15.10% per year.

Back to Basics: PB Ratio


BioSpecifics Technologies PB Ratio Historical Data

The historical data trend for BioSpecifics Technologies's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioSpecifics Technologies PB Ratio Chart

BioSpecifics Technologies Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.63 7.08 4.61 4.52 3.36

BioSpecifics Technologies Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 3.36 3.21 3.48 2.87

Competitive Comparison of BioSpecifics Technologies's PB Ratio

For the Biotechnology subindustry, BioSpecifics Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioSpecifics Technologies's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioSpecifics Technologies's PB Ratio distribution charts can be found below:

* The bar in red indicates where BioSpecifics Technologies's PB Ratio falls into.



BioSpecifics Technologies PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BioSpecifics Technologies's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2020)
=88.53/18.423
=4.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


BioSpecifics Technologies  (NAS:BSTC) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BioSpecifics Technologies PB Ratio Related Terms

Thank you for viewing the detailed overview of BioSpecifics Technologies's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioSpecifics Technologies (BioSpecifics Technologies) Business Description

Traded in Other Exchanges
N/A
Address
35 Wilbur Street, Lynbrook, NY, USA, 11563
BioSpecifics Technologies Corp is a biopharmaceutical company that specializes in collagenase for multiple indications. Injectable collagenase is marketed in various geographic regions, including the U.S., the EU, and Australia, under the Xiaflex name. The targeted diseases are Dupuytren's contracture and Peyronie's disease. The company is also researching the development of Xiaflex as a solution for new potential indications, such as uterine fibroids, adhesive capsulitis, cellulite, lateral hip fat, plantar fibromatosis, and human and canine lipomas.
Executives
Paul Gitman director 167 EXECUTIVE DRIVE MANHASSET HILLS NY 11040
Michael Schamroth director 191 MEADOWVIEW AVENUE HEWLETT NY 11557
Toby Wegman director, 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487
Mark N Wegman director 43 OVERLOOK ROAD OSSINING NY 10562
Jennifer M Chao director 7 PURITAN WOODS ROAD, RYE NY 10580
Joseph Truitt director, officer: Chief Executive Officer C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Michael A. Sherman director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Fishman Corey N. director DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Patrick Hutchison officer: Chief Financial Officer C/O BIOSPECIFICS TECHNOLOGIES CORP 2 RIGHTER PARKWAY SUITE 200 WILMINGTON DE 19803
J Kevin Buchi director, officer: Chief Executive Officer 41 MOORES ROAD, FRAZER PA 19355
Patrick M Caldwell officer: Principal Financial Officer C/O PROTINE DESIGN LAB 532 BELLA CALAIS WAY SAN JOSE CA 94138
Jyrki Mattila director AUXILIUM PHARMACEUTICALS, INC., 40 VALLEY STREAM PARKWAY, MALVERN PA 19355
Ronald Edward Law officer: SVP Business Development 23733 N. LOOKOUT PT. ROAD, LAKE BARRINGTON IL 60010
Thomas Wegman director, 10 percent owner, officer: President 1764 BRIAR PLACE MERRICK NY 11566
Estate Of Edwin H. Wegman 10 percent owner 4092 BOCAIRE BLVD. BOCA RATON FL 33487

BioSpecifics Technologies (BioSpecifics Technologies) Headlines